bcx9930
Small moleculeexperimental
Clinical trial activity
6 trials · 7 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Mar 3, 2020 (NCT04330534)
Timeline
Indications
Mechanism of action
- Complement factor DINHIBITOR
CFD inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05741346 | Phase 2 | Jan 18, 2023 | Beneficência Portuguesa de Sao Paulo, BioCryst |
| NCT05116774 | Phase 2 | Nov 30, 2021 | BioCryst, University of London |
| NCT05162066 | Phase 2 | Oct 29, 2021 | BioCryst, University of Iowa |
| NCT05116787 | Phase 2 | Oct 26, 2021 | BioCryst, Harvard University |
| NCT04702568 | Phase 2 | Dec 18, 2020 | BioCryst, University of Leeds |
| NCT04330534 | Phase 1/Phase 2 (Phase 2) | Mar 3, 2020 | BioCryst, University of Naples Frederico II |
Showing 6 of 6 trials
Page 1 / 1
Organizations
Research & Development (7)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| BioCryst | For profit | 6 | 6 | 1 | 2020 |
| Beneficência Portuguesa de Sao Paulo | Academic/Hospital | 1 | 0 | 1 | 2023 |
| Harvard University | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Iowa | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Leeds | Academic/Hospital | 1 | 0 | 1 | 2020 |
| University of London | Academic/Hospital | 1 | 0 | 1 | 2021 |
| University of Naples Frederico II | Academic/Hospital | 1 | 0 | 1 | 2020 |
7 organizations
Page 1 / 1